Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B

Zoetis Inc.

2025-FY EPS reported $6.02 revenue$9,467,000,000

Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).
Full year 2025 revenue $9.5B (+2% reported, +6% organic); adjusted EPS $6.41 (+8% reported).
FY 2026 guidance: revenue $9.825-10.025B (organic growth 3-5%); adjusted EPS $7.00-7.10.
U.S. segment revenue flat organically; International up 7% organic driven by parasiticide and livestock growth.
Acquired VPG in UK/Ireland; received approvals for long-acting OA pain mAbs Lenivia (dog) and Portela (cat) in Canada/EU.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.